Vaccinia Virus Exhibits Cell-type-dependent Entry Characteristics

Overview

Journal Virology

Specialty Microbiology

Date 2009 Jan 24

PMID 19162290

Citations 35

Authors

J Charles Whitbeck

Chwan-Hong Foo

Manuel Ponce de Leon

Roselyn J Eisenberg

Gary H Cohen

Affiliations

Soon will be listed here.

Abstract

Differing and sometimes conflicting data have been reported regarding several aspects of vaccinia virus (VV) entry. To address this, we used a beta-galactosidase reporter virus to monitor virus entry into multiple cell types under varying conditions. Entry into HeLa, B78H1 and L cells was strongly inhibited by heparin whereas entry into Vero and BSC-1 cells was unaffected. Bafilomycin also exhibited variable and cell-type-specific effects on VV entry. Entry into B78H1 and BSC-1 cells was strongly inhibited by bafilomycin whereas entry into Vero and HeLa cells was only partially inhibited suggesting the co-existence of both pH-dependent and pH-independent VV entry pathways in these cell types. Finally, entry into HeLa, B78H1, L and BSC-1 cells exhibited a lag of 6-9 min whereas this delay was undetectable in Vero cells. Our results suggest that VV exploits multiple cell attachment and entry pathways allowing it to infect a broad range of cells.

Citing Articles

The vaccinia chondroitin sulfate binding protein drives host membrane curvature to facilitate fusion.

Pokorny L, Burden J, Albrecht D, Bamford R, Leigh K, Sridhar P EMBO Rep. 2024; 25(3):1310-1325.

PMID: 38321165 PMC: 10933376. DOI: 10.1038/s44319-023-00040-2.

The evolving epidemiology of monkeypox virus.

Li H, Zhang H, Ding K, Wang X, Sun G, Liu Z Cytokine Growth Factor Rev. 2022; 68:1-12.

PMID: 36244878 PMC: 9547435. DOI: 10.1016/j.cytogfr.2022.10.002.

Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy.

Aalipour A, Le Boeuf F, Tang M, Murty S, Simonetta F, Lozano A Mol Ther Oncolytics. 2020; 17:232-240.

PMID: 32346612 PMC: 7183102. DOI: 10.1016/j.omto.2020.03.018.

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Lane T, Massey C, Comer J, Anantpadma M, Freundlich J, Davey R PLoS Negl Trop Dis. 2019; 13(11):e0007890.

PMID: 31751347 PMC: 6894882. DOI: 10.1371/journal.pntd.0007890.

The Vaccinia Virus (VACV) B1 and Cellular VRK2 Kinases Promote VACV Replication Factory Formation through Phosphorylation-Dependent Inhibition of VACV B12.

Rico A, Wang Z, Olson A, Linville A, Bullard B, Weaver E J Virol. 2019; 93(20).

PMID: 31341052 PMC: 6798115. DOI: 10.1128/JVI.00855-19.

References

Lin C, Chung C, Heine H, Chang W . Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol. 2000; 74(7):3353-65. PMC: 111837. DOI: 10.1128/jvi.74.7.3353-3365.2000. View

Aldaz-Carroll L, Whitbeck J, Ponce de Leon M, Lou H, Pannell L, Lebowitz J . Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology. 2005; 341(1):59-71. DOI: 10.1016/j.virol.2005.07.006. View

Highlander S, Sutherland S, Gage P, Johnson D, Levine M, Glorioso J . Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol. 1987; 61(11):3356-64. PMC: 255929. DOI: 10.1128/JVI.61.11.3356-3364.1987. View

Fogg C, Lustig S, Whitbeck J, Eisenberg R, Cohen G, Moss B . Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol. 2004; 78(19):10230-7. PMC: 516428. DOI: 10.1128/JVI.78.19.10230-10237.2004. View

Mayr A . Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis. 2003; 26(5-6):423-30. DOI: 10.1016/S0147-9571(03)00025-0. View

Aldaz-Carroll L, Whitbeck J, Ponce de Leon M, Lou H, Hirao L, Isaacs S . Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol. 2005; 79(10):6260-71. PMC: 1091701. DOI: 10.1128/JVI.79.10.6260-6271.2005. View

Huang C, Lu T, Bair C, Chang Y, Jwo J, Chang W . A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis. J Virol. 2008; 82(16):7988-99. PMC: 2519564. DOI: 10.1128/JVI.00894-08. View

Bisht H, Weisberg A, Moss B . Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol. 2008; 82(17):8687-94. PMC: 2519644. DOI: 10.1128/JVI.00852-08. View

Banfield B, LEDUC Y, Esford L, Schubert K, Tufaro F . Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol. 1995; 69(6):3290-8. PMC: 189040. DOI: 10.1128/JVI.69.6.3290-3298.1995. View

10.

Gruenheid S, Gatzke L, Meadows H, Tufaro F . Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans. J Virol. 1993; 67(1):93-100. PMC: 237341. DOI: 10.1128/JVI.67.1.93-100.1993. View

11.

Chang A, Metz D . Further investigations on the mode of entry of vaccinia virus into cells. J Gen Virol. 1976; 32(2):275-82. DOI: 10.1099/0022-1317-32-2-275. View

12.

Hsiao J, Chung C, Chang W . Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol. 1999; 73(10):8750-61. PMC: 112896. DOI: 10.1128/JVI.73.10.8750-8761.1999. View

13.

Whitbeck J, Peng C, Lou H, Xu R, Willis S, Ponce de Leon M . Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol. 1997; 71(8):6083-93. PMC: 191868. DOI: 10.1128/JVI.71.8.6083-6093.1997. View

14.

Janeczko R, Rodriguez J, Esteban M . Studies on the mechanism of entry of vaccinia virus in animal cells. Arch Virol. 1987; 92(1-2):135-50. DOI: 10.1007/BF01310068. View

15.

Olofsson S, Bergstrom T . Glycoconjugate glycans as viral receptors. Ann Med. 2005; 37(3):154-72. DOI: 10.1080/07853890510007340. View

16.

Ho Y, Hsiao J, Yang M, Chung C, Peng Y, Lin T . The oligomeric structure of vaccinia viral envelope protein A27L is essential for binding to heparin and heparan sulfates on cell surfaces: a structural and functional approach using site-specific mutagenesis. J Mol Biol. 2005; 349(5):1060-71. DOI: 10.1016/j.jmb.2005.04.024. View

17.

Vanderplasschen A, Hollinshead M, Smith G . Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol. 1998; 79 ( Pt 4):877-87. DOI: 10.1099/0022-1317-79-4-877. View

18.

Earl P, Americo J, Wyatt L, Eller L, Whitbeck J, Cohen G . Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004; 428(6979):182-5. DOI: 10.1038/nature02331. View

19.

Payne L, Norrby E . Adsorption and penetration of enveloped and naked vaccinia virus particles. J Virol. 1978; 27(1):19-27. PMC: 354136. DOI: 10.1128/JVI.27.1.19-27.1978. View

20.

Carter G, Law M, Hollinshead M, Smith G . Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol. 2005; 86(Pt 5):1279-1290. DOI: 10.1099/vir.0.80831-0. View